An angiogenic approach to osteoanabolic therapy targeting the SHN3-SLIT3 pathway
Bone · 2023
DOI: 10.1016/j.bone.2023.116761 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bone, 2023. Verfasst von Alisha R Yallowitz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, United States of America. Hauptthemen laut MEDLINE: Endothelial Cells, DNA-Binding Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Pershing Square Sohn Cancer Research Alliance, National Natural Science Foundation of China.
Abstract (Originalsprache)
Often, disorders of impaired bone formation involve not only a cell intrinsic defect in the ability of osteoblasts to form bone, but moreover a broader dysfunction of the skeletal microenvironment that limits osteoblast activity. Developing approaches to osteoanabolic therapy that not only augment osteoblast activity but moreover correct this microenvironmental dysfunction may enable both more effective osteoanabolic therapies and also addressing a broader set of indications where vasculopathy or other forms microenvironment dysfunction feature prominently. We here review evidence that SHN3 acts as a suppressor of not only the cell intrinsic bone formation activity of osteoblasts, but moreover of the creation of a local osteoanabolic microenvironment. Mice lacking Schnurri3 (SHN3, HIVEP3) display a very robust increase in bone formation, that is due to de-repression of ERK pathway signaling in osteoblasts. In addition to loss of SHN3 augmenting the differentiation and bone formation activity of osteoblasts, loss of SHN3 increases secretion of SLIT3 by osteoblasts, which in a skeletal context acts as an angiogenic factor. Through this angiogenic activity, SLIT3 creates an osteoanabolic microenvironment, and accordingly treatment with SLIT3 can increase bone formation and enhance fracture healing. These features both validate vascular endothelial cells as a therapeutic target for disorders of low bone mass alongside the traditionally targeted osteoblasts and osteoclasts and indicate that targeting the SHN3/SLIT3 pathway provides a new mechanism to induce therapeutic osteoanabolic responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, United States of America.
- Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, USA; Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA; Li Weibo Inst…
- The First Affiliated Hospital of Xiamen University-ICMRS Collaborating Center for Skeletal Stem Cells, State Key Laboratory of Cellular Stress Biology, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 36…
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, United States of America; Research Division, Hospital for Special Surgery, New York, NY 10065, United States of America…
Förderung
- NIAMS NIH HHS
- Pershing Square Sohn Cancer Research Alliance
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- National Institutes of Health
- Burroughs Wellcome Fund
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Yallowitz, A. R., Shim, J. H., Xu, R., & Greenblatt, M. B. (2023). An angiogenic approach to osteoanabolic therapy targeting the SHN3-SLIT3 pathway. Bone. https://doi.org/10.1016/j.bone.2023.116761
Vancouver
Yallowitz AR, Shim JH, Xu R, Greenblatt MB. An angiogenic approach to osteoanabolic therapy targeting the SHN3-SLIT3 pathway. Bone. 2023. doi:10.1016/j.bone.2023.116761
BibTeX
@article{Yallowitz2023,
author = {Yallowitz, Alisha R and Shim, Jae-Hyuck and Xu, Ren and Greenblatt, Matthew B},
title = {An angiogenic approach to osteoanabolic therapy targeting the SHN3-SLIT3 pathway},
journal = {Bone},
year = {2023},
doi = {10.1016/j.bone.2023.116761}
}
EUVIMED